StayCurrentMD · Clinical Characteristics and Prognosis of Biliary Atresia with Low Serum Matrix Metalloproteinase-7 Levels
Article1 min read·Published Dec 2023Older

Clinical Characteristics and Prognosis of Biliary Atresia with Low Serum Matrix Metalloproteinase-7 Levels

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Dec 2023 · 1 min read

In brief

In brief

This study examines biliary atresia patients with unexpectedly low serum MMP-7 levels, investigating why this diagnostic biomarker fails to elevate in certain cases. Understanding these atypical presentations helps clinicians avoid missed diagnoses when relying on MMP-7 screening for differentiating BA from other causes of infant cholestasis.

  • Serum MMP-7 is a reliable biomarker to distinguish biliary atresia from other causes of neonatal cholestasis.
  • A subset of BA patients present with normal or only slightly elevated MMP-7 levels, creating diagnostic challenges.
  • Low MMP-7 in confirmed BA cases may correlate with distinct clinical phenotypes or disease severity patterns.
  • Clinicians should not exclude BA diagnosis based solely on low MMP-7; additional workup remains essential.
  • Understanding MMP-7 variability in BA can improve risk stratification and prognostic counseling for families.

Written by the GCMD Library team from the article.

Serum matrix metalloproteinase-7 (MMP-7) levels can precisely differentiate biliary atresia (BA) from non-BA cholestasis. However, serum MMP-7 levels of some BA patients were within normal range or slightly elevated. This study aimed to investigate the clinical characteristics and prognosis of biliary atresia with low serum MMP-7 levels.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →